Study provides new insight on how HER2-low tumors may evolve in breast cancer patient
 

The finding that breast tumors can evolve to express low HER2 potentially widens the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate therapies, that are currently in clinical trials for HER2-low tumors.

More...